Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial

Background: Chemoimmunotherapy is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this combination treatment in patients with metastatic soft tissue sarcoma (STS) are currently limited. This study evaluated the safety and efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhichao, Dong, Shuping, Zuo, Wenli, Li, Po, Zhang, Fan, Gao, Shilei, Yang, Yonghao, Li, Chao, Zhang, Peng, Wang, Xin, Wang, Jiaqiang, Yao, Weitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793899/
https://www.ncbi.nlm.nih.gov/pubmed/36582535
http://dx.doi.org/10.3389/fphar.2022.987569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793899/
https://www.ncbi.nlm.nih.gov/pubmed/36582535
http://dx.doi.org/10.3389/fphar.2022.987569

Ejemplares similares